Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in pediatric ANCA-associated glomerulonephritis induction remission
ChiCTR2100050955Phase 4Recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in antineutrophil cytoplasmic antibodies-associated glomerulonephritis (ANCA-GN), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), sponsored by Children's Hospital of Fudan University. Primary endpoints: urine protein, kidney function and 2 more. Started Sep 2021; status: recruiting.
02
Drugs
rituximab
03
Conditions
antineutrophil cytoplasmic antibodies-associated glomerulonephritis (ANCA-GN)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on ChiCTR2100050955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050955.